NEW YORK (GenomeWeb) – Chinese firms Shuwen Biotech and Jiangsu Hengrui Medicine today announced a collaboration to develop companion diagnostics.

Under the term of the agreement, Shuwen will develop assays and kits for an unidentified anticancer drug candidate that Hengrui is currently developing. Shuwen will also screen patients with the tests at its diagnostic reference laboratories for upcoming clinical trials, as well as manufacture and market the diagnostic if it receives regulatory approval.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.